CARE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN COMBINATION WITH ARTERIAL HYPERTENSION
Abstract
Management of patients suffering from chronic obstructive pulmonary disease (COPD) in combination with arterial hypertension (AH), as well as any other concomitant pathology, seems to be a very urgent problem due to the widespread prevalence of these diseases in the adult population. According to various authors, the frequency of hypertension in patients with COPD varies in a fairly wide range – from 6.8 to 76.3%, averaging 35% [1–4]. On the other hand, COPD is detected in every 4th patient with hypertension aged 25 to 64 years [5]. The increase in the number of patients with a combination of hypertension and COPD is due to both an increase in morbidity and an increase in the geriatric population of patients in whom these diseases are very common [6, 7]. The modern concept of COPD, developed by experts from the World Health Organization, emphasizes that the severity and prognosis of COPD are often determined by extrapulmonary manifestations of the disease, primarily cardiovascular pathology, which is characterized by the greatest clinical and social significance. This position is worthy of reflection in the new program for the Global Strategy for the Diagnosis, Treatment and Prevention of COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD, revision 2011) [8].
References
Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333.
Zadionchenko V.S. Arterial hypertension in chronic obstructive pulmonary disease. 2005; With. 10–2.
Paleev N.R., Raspopina N.A., Fedorova S.I. etc. Does “pulmogenic hypertension” exist? Cardiology. 2002; 6:51–3.
Karoli N.A., Rebrov A.P. Comorbidity in patients with chronic obstructive pulmonary disease: the place of cardiovascular pathology. Rational pharmacotherapy in cardiology. 2009; 4:9–16.
Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD 2012; 9 (2): 131–41.
Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest 2005; 127(6):1952–9.
Dogra S, Ardern C, Baker J. The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma 2007; 44:849–54.
Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention for Chronic Obstructive Lung Diseases (Revised 2011). Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease. Revision 2011 Trans. from English language edited by A.S. Belevsky. M.: Russian Respiratory Society, 2012; With. 80.
Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respire Crit Care Med 2002; 166:333–9.
Hole DJ, Watt GC, Davey-Smith G et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313(7059):711–5.
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2 (1): 8–11.
Olbinskaya L.I., Belov A.A., Opalenkov F.V. Daily blood pressure profile in chronic obstructive pulmonary diseases and in combination with arterial hypertension. Ross. cardiol. magazine 2000; 2 (22): 20–5.
Zhdanov V.F. Clinical and statistical characteristics of patients with nonspecific lung diseases with systemic arterial hypertension. Current problems of pulmonology. Sat. scientific tr. L., 1991; With. 89–93.
Suylen RI, Smits JF, Daemen MJ. Pulmonary artery remodeling difference in hypoxia and monocrotaline induced pulmonary hypertension. Am J Respir Crit Care Med 1998; 157:1423–8.
Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary disease. Circulation 2001; 104:263–8.
Lucher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118(Suppl.): S81–90.
Goloshubina V.V. Arterial hypertension in patients with chronic obstructive pulmonary disease: clinical and anatomical parallels, principles of program treatment and rehabilitation. Author's abstract. dis. ...cand. honey. Sci. Omsk,. 2007.
Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention for Chronic Obstructive Lung Diseases (Revised 2011). Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease. Revision 2011 Trans. from English language edited by A.S. Belevsky. M.: Russian Respiratory Society, 2012; With. 63.
National recommendations for the diagnosis and treatment of arterial hypertension. VNOK, 2010.
Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31:204–12.
Soriano JB, Visick GT, Muellerova H et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128:2099–107.
Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101–7.
Sebastian JL, McKinney WP, Kaufman J, Young MJ. Angiotensin-converting enzyme inhibitors and cough: prevalence in an outpatient medical clinic population. Chest 1991; 99: 36–9.
Israiliz H, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117:234–42.
Ovcharenko S.I., Litvinova I.V., Makolkin V.I. Selective adrenergic blockers (nebivolol and metoprolol succinate) in the treatment of patients with arterial hypertension and/or coronary heart disease in combination with broncho-obstructive syndrome: assessment of effectiveness and safety. Pulmonology. 2008; 3:28–34.
Ovcharenko S.I., Litvinova I.V., Makolkin V.I. Successful use of the cardioselective β-blocker nebivolol in patients with arterial hypertension and/or coronary heart disease and broncho-obstructive syndrome. Ross. cardiol. magazine 2007; 4:15–23.
Necroutenko L, Agafonov A, Lykova D. Effect of Indapamide on intima-media thickness and arterial dilatation in elderly hypertensives. 12th European Meeting on Hypertension. Prague, 2002.
Schini VB, Dewey J, Vanhoutte PM. Indapamide potentiates the endothelium-dependent relaxation in isolated canine femoral arteries. Am J Card 1990; 65 (17): 6H–10H.
Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351:1755–62.
Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465–75.
Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type2 diabetes: the NESTOR study. J Hypertens 2004; 22: 1613–22. 32. Amonov Muhammad Komil o'g'li// Orientation to Acute Kidney Injury in Covid-19 //JOURNAL OF ADVANCED RESEARCH AND STABILITY (JARS), Vol. 1 No. 5 (2021). 33. Amonov M.K. (2021). Acute Kidney Damage from Coronavirus Disease (Review Article). Central Asian Journal of Medical and Natural Science, 378-382.https://doi.org/10.47494/cajmns.vi0.447
Amonov, Muhammad Komil Ogli. "RISK FACTORS FOR SEVERE AND CRITICAL PATIENTS WITH COVID-19" Oriental renaissance: Innovative, educational, natural and social sciences, vol. 1, no. 10, 2021, pp. 1080-1084.
